Rein Therapeutics vs Tvardi Therapeutics
RNTX and TVRD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RNTX and TVRD compare
Rein Therapeutics is the larger company, worth 2.3 times as much as Tvardi Therapeutics ($30.7M against $13.5M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RNTX | TVRD |
|---|---|---|
| Size and price | ||
| Market cap | $30.7M | $13.5M |
| Share price | $0.356 | $1.01 |
| Change, 1 year | −71.5% | −74.9% |
| Change, 5 years | −97.3% | −99.8% |
| Beta (5Y) | 2.30 | 2.82 |
| Employees | 10 | 12 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 1.6× |
| Profitability | ||
| Return on equity | −96.4% (better) | −126% |
| Return on invested capital | −145% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.27 (better) | 1.87 |
| Altman Z-score | −8.96 (better) | −13.58 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | 0.00% |
| Years of dividend growth | 0 | 0 |
| Buyback yield | −179% | – |
| Shareholder yield | −179% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 47.3% | 16.7% |
| Held by insiders | 9.6% | 15.6% |
| Insider net buying, 12 months | $74.7K | – |
| Short interest, % of float | 0.91% | 2.7% |
Go deeper
- RNTX stock overview
- RNTX income statement
- RNTX valuation and score
- TVRD stock overview
- TVRD income statement
- TVRD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.